Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

被引：0

作者：

David F. McDermott

Mahrukh A. Huseni

Michael B. Atkins

Robert J. Motzer

Brian I. Rini

Bernard Escudier

Lawrence Fong

Richard W. Joseph

Sumanta K. Pal

James A. Reeves

Mario Sznol

John Hainsworth

W. Kimryn Rathmell

Walter M. Stadler

Thomas Hutson

Martin E. Gore

Alain Ravaud

Sergio Bracarda

Cristina Suárez

Riccardo Danielli

Viktor Gruenwald

Toni K. Choueiri

Dorothee Nickles

Suchit Jhunjhunwala

Elisabeth Piault-Louis

Alpa Thobhani

Jiaheng Qiu

Daniel S. Chen

Priti S. Hegde

Christina Schiff

Gregg D. Fine

Thomas Powles

机构：

[1] Beth Israel Deaconess Medical Center,

[2] Genentech,undefined

[3] Inc.,undefined

[4] Georgetown Lombardi Comprehensive Cancer Center,undefined

[5] Memorial Sloan Kettering Cancer Center,undefined

[6] Cleveland Clinic Taussig Cancer Institute,undefined

[7] Gustave Roussy,undefined

[8] University of California,undefined

[9] San Francisco School of Medicine,undefined

[10] Mayo Clinic Hospital –Florida,undefined

[11] City of Hope Comprehensive Cancer Center,undefined

[12] Florida Cancer Specialists,undefined

[13] Yale School of Medicine,undefined

[14] Sarah Cannon Research Institute,undefined

[15] Vanderbilt University Medical Center,undefined

[16] University of Chicago Medicine,undefined

[17] Texas Oncology – Baylor Charles A. Sammons Cancer Center,undefined

[18] Royal Marsden Hospital,undefined

[19] CHU Hopitaux de Bordeaux – Hôpital Saint-André,undefined

[20] Ospedale San Donato,undefined

[21] Azienda USL Toscana Sudest,undefined

[22] Vall d’Hebron Institute of Oncology,undefined

[23] Vall d’Hebron University Hospital,undefined

[24] Universitat Autònoma de Barcelona,undefined

[25] Azienda Ospedaliera Universitaria Senese,undefined

[26] Center for Immune-Oncology,undefined

[27] Medizinische Hochschule,undefined

[28] Zentrum Innere Medizin,undefined

[29] Abt. Hämatologie u. Onkologie,undefined

[30] Dana-Farber Cancer Institute,undefined

[31] Roche Products Ltd,undefined

[32] Barts Cancer Institute and the Royal Free Hospital,undefined

[33] Queen Mary University of London,undefined

来源：

Nature Medicine | 2018年 / 24卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

In the version of this article originally published, there was an error in Fig. 2n. The top line of the HR comparison chart originally was Atezo + bev vs sun. It should have been Atezo + bev vs atezo. The error has been corrected in the HTML and PDF versions of this article.

引用

页码：1941 / 1941

共 50 条

[21] Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
Jeffrey J. Wallin
Johanna C. Bendell
Roel Funke
Mario Sznol
Konstanty Korski
Suzanne Jones
Genevive Hernandez
James Mier
Xian He
F. Stephen Hodi
Mitchell Denker
Vincent Leveque
Marta Cañamero
Galina Babitski
Hartmut Koeppen
James Ziai
Neeraj Sharma
Fabien Gaire
Daniel S. Chen
Daniel Waterkamp
Priti S. Hegde
David F. McDermott
Nature Communications, 7
[22] Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
Wallin, Jeffrey J.
Bendell, Johanna C.
Funke, Roel
Sznol, Mario
Korski, Konstanty
Jones, Suzanne
Hernandez, Genevive
Mier, James
He, Xian
Hodi, F. Stephen
Denker, Mitchell
Leveque, Vincent
Canamero, Marta
Babitski, Galina
Koeppen, Hartmut
Ziai, James
Sharma, Neeraj
Gaire, Fabien
Chen, Daniel S.
Waterkamp, Daniel
Hegde, Priti S.
McDermott, David F.
NATURE COMMUNICATIONS, 2016, 7
[23] Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial
Powles, Thomas
Atkins, Michael B.
Escudier, Bernard
Motzer, Robert J.
Rini, Brian, I
Fong, Lawrence
Joseph, Richard W.
Pal, Sumanta K.
Sznol, Mario
Hainsworth, John
Stadler, Walter M.
Hutson, Thomas E.
Ravaud, Alain
Bracarda, Sergio
Suarez, Cristina
Choueiri, Toni K.
Reeves, James
Cohn, Allen
Ding, Beiying
Leng, Ning
Hashimoto, Kenji
Huseni, Mahrukh
Schiff, Christina
McDermott, David F.
EUROPEAN UROLOGY, 2021, 79 (05) : 665 - 673
[24] Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma
Rini, Brian I.
Michaelson, M. Dror
Rosenberg, Jonathan E.
Bukowski, Ronald M.
Sosman, Jeffrey A.
Stadler, Walter M.
Hutson, Thomas E.
Margolin, Kim
Harmon, Charles S.
DePrimo, Samuel E.
Kim, Sindy T.
Chen, Isan
George, Daniel J.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) : 3743 - 3748
[25] Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting
Beuselinck, Benoit
Job, Sylvie
Becht, Etienne
Karadimou, Alexandra
Verkarre, Virginie
Couchy, Gabrielle
Giraldo, Nicolas
Rioux-Leclercq, Nathalie
Molinie, Vincent
Sibony, Mathilde
Elaidi, Reza
Teghom, Corinne
Patard, Jean-Jacques
Mejean, Arnaud
Fridman, Wolf Herman
Sautes-Fridman, Catherine
de Reynies, Aurelien
Oudard, Stephane
Zucman-Rossi, Jessica
CLINICAL CANCER RESEARCH, 2015, 21 (06) : 1329 - 1339
[26] Interrogating the Significance of PARP1 Expression and PBRM1 Mutation as Biomarkers for Predicting the Response to Atezolizumab plus Bevacizumab or to Sunitinib in Patients with Clear Cell Renal Cell Carcinoma
Lanillos, Javier
Santos, Maria
Valdivia, Carlos
Mora, Alberto
Rodriguez-Antona, Cristina
EUROPEAN UROLOGY, 2022, 82 (03) : 334 - 335
[27] Clinical activity, immune and molecular correlates of nivolumab vs. nivolumab plus bevacizumab vs nivolumab plus ipilimumab in metastatic renal cell carcinoma
Gao, Jianjun
Karam, Jose A.
Wood, Christopher G.
Matin, Surena
Ahrar, Kamran
Jonasch, Eric
Tannir, Nizar
Campell, Matthew
Ng, Chaan S.
Slack, Rebecca S.
Rao, Priya
Allison, James P.
Blando, Jorge M.
Vence, Luis M.
Basu, Sreyashi
Zhao, Hao
Chen, Tenghui
Chen, Hong
Sharma, Padmanee
CANCER RESEARCH, 2017, 77
[28] IMmotion151: A randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic Renal Cell Carcinoma (mRCC)
Gruellich, C.
Motzer, R. J.
Powles, T.
Atkins, M.
Escudier, B. J.
McDermott, D.
Suarez, C.
Bracarda, S.
Stadler, W.
Donskov, F.
Lee, J. L.
Hawkins, R.
Ravaud, A.
Alekseev, B.
Staehler, M.
Uemura, M.
Donaldson, F.
Li, S.
Huseni, M.
Schiff, C.
Rini, B. I.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 41 - 42
[29] Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study
Lindskog, Magnus
Laurell, Anna
Kjellman, Anders
Melichar, Bohuslav
Rey, Pablo Maroto
Zielinski, Henryk
Villacampa, Felipe
Bigot, Pierre
Zoltan, Bajory
Parikh, Omi
Alba, David Vazquez
Jellvert, Dsa
Flasko, Tibor
Gallardo, Enrique
Caparros, Maria Jose Ribal
Purkalne, Gunta
Suenaert, Peter
Karlsson-Parra, Alex
Ljungberg, Borje
EUROPEAN UROLOGY OPEN SCIENCE, 2022, 40 : 38 - 45
[30] IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC)
Motzer, Robert J.
Powles, Thomas
Atkins, Michael B.
Escudier, Bernard
McDermott, David F.
Suarez, Cristina
Bracarda, Sergio
Stadler, Walter Michael
Donskov, Frede
Lee, Jae-Lyun
Hawkins, Robert E.
Ravaud, Alain
Alekseev, Boris Y.
Staehler, Michael D.
Uemura, Motohide
Donaldson, Francis
Li, Shi
Huseni, Mahrukh A.
Schiff, Christina
Rini, Brian I.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)

← 1 2 3 4 5 →